Literature DB >> 23147980

Hypothalamic-pituitary-adrenal axis suppression in asthmatic school children.

Ekkehard Werner Zöllner1, Carl J Lombard, Ushma Galal, F Stephen Hough, Elvis M Irusen, Eugene Weinberg.   

Abstract

BACKGROUND AND
OBJECTIVE: Hypothalamic-pituitary-adrenal axis suppression (HPAS) when treating children with corticosteroids is thought to be rare. Our objective was to determine the prevalence of and predictive factors for various degrees of HPAS.
METHODS: Clinical features of HPAS, doses, adherence, asthma score, and lung functions were recorded in 143 asthmatic children. The overnight metyrapone test was performed if morning cortisol was >83 nmol/L. Spearman correlations coefficients (r) were calculated between 3 postmetyrapone outcomes and each continuous variable. A multiple linear regression model of √postmetyrapone adrenocorticotropic hormone (ACTH) and a logistic regression model for HPAS were developed.
RESULTS: Hypocortisolemia was seen in 6.1% (1.8-10.5), hypothalamic-pituitary suppression (HPS) in 22.2% (14.5-29.9), adrenal suppression in 32.3% (23.7-40.9), HPAS in 16.3% (9.3-23.3), and any hypothalamic-pituitary-adrenal axis dysfunction in 65.1% (56.5-72.9). Log daily nasal steroid (NS) dose/m(2) was associated with HPAS in the logistic regression model (odds ratio = 3.7 [95% confidence interval: 1.1-13.6]). Daily inhaled corticosteroids (ICSs) + NS dose/m(2) predicted HPAS in the univariate logistic regression model (P = .038). Forced expiratory volume in 1 second/forced vital capacity <80% was associated with HPAS (odds ratio = 4.1 [95% confidence interval: 1.0-14.8]). Daily ICS + NS/m(2) dose was correlated with the postmetyrapone ACTH (r = -0.29, P < .001). BMI (P = .048) and percent adherence to ICS (P < .001) and NS (P = .002) were predictive of √postmetyrapone ACTH (R(2) = .176).
CONCLUSIONS: Two-thirds of children on corticosteroids may have hypothalamic-pituitary-adrenal axis dysfunction. In one-third, central function had recovered but adrenal suppression persisted. Predictive factors for HPAS are NS use, BMI, and adherence to ICS and NS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23147980     DOI: 10.1542/peds.2012-1147

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  19 in total

1.  Long-Term Cortisol Concentration in Scalp Hair of Asthmatic Children Using Inhaled Corticosteroids: A Case-Control Study.

Authors:  Maaike P Smit; Ed H G van Leer; Gerard Noppe; Yolanda B de Rijke; Dieneke Kramer van Driel; Erica L T van den Akker
Journal:  Horm Res Paediatr       Date:  2017-07-14       Impact factor: 2.852

Review 2.  Asthma and Medicines - Long-Term Side-Effects, Monitoring and Dose Titration.

Authors:  Satnam Kaur; Varinder Singh
Journal:  Indian J Pediatr       Date:  2018-01-06       Impact factor: 1.967

Review 3.  Recovery of steroid induced adrenal insufficiency.

Authors:  Areej K Younes; Noor K Younes
Journal:  Transl Pediatr       Date:  2017-10

Review 4.  Diagnosis and management of pediatric adrenal insufficiency.

Authors:  Ahmet Uçar; Firdevs Baş; Nurçin Saka
Journal:  World J Pediatr       Date:  2016-04-08       Impact factor: 2.764

5.  Paediatrics: High prevalence of HPA axis suppression in children taking corticosteroids.

Authors:  Joana Osório
Journal:  Nat Rev Endocrinol       Date:  2012-12-04       Impact factor: 43.330

Review 6.  Benefits and Risks of Long-Term Asthma Management in Children: Where Are We Heading?

Authors:  Hengameh H Raissy; H William Kelly
Journal:  Drug Saf       Date:  2017-03       Impact factor: 5.606

7.  Expression and targeting of lymphocyte function-associated antigen 1 (LFA-1) on white blood cells for treatment of allergic asthma.

Authors:  Anukriti Gupta; Vanessa Espinosa; Lindsey E Galusha; Vahid Rahimian; Katie L Miro; Amariliz Rivera-Medina; Chinnaswamy Kasinathan; Eugenio Capitle; Helen A Aguila; Scott C Kachlany
Journal:  J Leukoc Biol       Date:  2014-10-23       Impact factor: 4.962

8.  Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice.

Authors:  Brigitte Benard; Valérie Bastien; Benjamin Vinet; Roger Yang; Maja Krajinovic; Francine M Ducharme
Journal:  Eur Respir J       Date:  2017-08-17       Impact factor: 16.671

9.  Evidence of hypothalamic-pituitary-adrenal axis suppression during moderate-to-high-dose inhaled corticosteroid use.

Authors:  Ozlem Cavkaytar; Dogus Vuralli; Ebru Arik Yilmaz; Betul Buyuktiryaki; Ozge Soyer; Umit M Sahiner; Nurgun Kandemir; Bulent E Sekerel
Journal:  Eur J Pediatr       Date:  2015-08-09       Impact factor: 3.183

10.  Methylprednisolone Pulse Treatment of Graves' Ophthalmopathy Is Not Associated with Secondary Adrenocortical Insufficiency.

Authors:  Sofie Jespersen; Birte Nygaard; Lars Østergaard Kristensen
Journal:  Eur Thyroid J       Date:  2015-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.